Boston Scientific Corporation $BSX Shares Sold by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. has reduced its stake in Boston Scientific by 71.8%, owning only 2,369 shares valued at $239,000 after selling 6,020 shares in Q1.
• Institutional investors control 89.07% of Boston Scientific's stock, with major increases in holdings by firms like Vanguard Group Inc. and Goldman Sachs Group Inc..
• Boston Scientific reported a Q2 EPS of $0.75, exceeding estimates, with revenue of $5.06 billion, marking a 22.8% year-over-year increase.

Fox Run Management L.L.C. decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 71.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,369 shares of the medical equipment provider's stock after selling 6,020 shares during the quarter. Fox Run Management L.L.C.'s holdings in Boston Scientific were worth $239,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Colonial Trust Co SC grew its holdings in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific in the 4th quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the 1st quarter valued at about $27,000. Finally, Ameriflex Group Inc. purchased a new stake in Boston Scientific in the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock valued at $35,976,603 over the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.46 on Monday, hitting $105.71. 2,194,256 shares of the stock traded hands, compared to its average volume of 7,534,855. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $156.64 billion, a PE ratio of 62.96, a PEG ratio of 2.56 and a beta of 0.66. Boston Scientific Corporation has a 1-year low of $78.90 and a 1-year high of $108.94. The company's fifty day moving average is $104.10 and its 200 day moving average is $102.12.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. UBS Group upped their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Raymond James Financial upped their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company upped their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.